Business Insider: JDRF T1D Fund Invests in Promising Type 1 Diabetes Commercial Opportunities

Grantee JDRF T1D Fund is investing in early-stage companies that need funding to identify and advance type 1 diabetes (T1D) therapies.

A Business Insider piece highlights Helmsley’s $5 million commitment to the Fund, which is the largest-ever outside commitment in the Fund’s history and is a continuation of a long-standing partnership between Helmsley and JDRF. The funds may allow T1D scientific advancements that would not otherwise reach patients to be translated into life-changing treatments.

Read the full piece at businessinsider.com.